Objective To compare the clinical efficacy and safety of insulin glargine and intermediateacting human insulin in the treatment of type 2 diabetes in the elderly. Methods A total of 60 elderly patients with type 2 diabetes were randomly divided into control group and observation group, with 30 cases in each group. The control group was treated with intermediate-acting human insulin, and the observation group was treated with insulin glargine. Comparison were made on fasting plasma glucose (FPG) and postprandial 2 h plasma glucose (PPG) before and after treatment, the time of blood glucose reaching the standard, the daily dosage of insulin and the occurrence of hypoglycemia events between the two groups. Results Before treatment, the observation group had FPG and PPG level respectively as (9.19±1.24) and (16.35±3.58) mmol/L, which were (9.22±1.19) and (16.21±3.64) mmol/L in the control group, and the difference was not statistically significant (P＞0.05). After treatment, the observation group had FPG and PPG level respectively as (5.98±1.04) and (9.41±1.58) mmol/L, which were (6.23±0.92) and (9.57±1.67) mmol/L in the control group. Both groups had lower FPG and PPG than those before treatment, and the difference was statistically significant (P＜0.05). There was no statistically significant difference in FPG and PPG (P＞0.05). After treatment, the observation group had shorter time of blood glucose reaching standard as (2.81±0.26) d than (3.24±0.64) d in the control group, less daily dosage of insulin as (0.65±0.07) IU/kg than (0.79±0.06) IU/kg in the control group, and lower incidence of hypoglycemic events as 13.33％ than 43.33％ in the control group. Their difference was statistically significant (P＜0.05). Conclusion Both insulin glargine and intermediate-acting human insulin can effectively control the blood glucose of elderly patients with type 2 diabetes. The former has lower incidence of hypoglycemia, less insulin, and shorter time of blood glucose reaching standard. Elderly patients with type 2 diabetes benefit more.%目的 比较甘精胰岛素与中效人胰岛素治疗老年2型糖尿病的临床疗效及安全性.方法 60例老年2型糖尿病患者, 随机分为对照组与观察组, 各30例.对照组给予中效人胰岛素进行治疗, 观察组给予甘精胰岛素进行治疗.对比两组治疗前后空腹血糖 (FPG) 、餐后血浆血糖 (PPG) 水平;血糖达标时间、胰岛素日用量以及低血糖事件发生情况.结果 治疗前, 观察组FPG、PPG水平分别为 (9.19±1.24) 、 (16.35±3.58) mmol/L, 对照组FPG、PPG水平分别为 (9.22±1.19) 、 (16.21±3.64) mmol/L, 对比差异无统计学意义 (P＞0.05) .治疗后, 观察组FPG、PPG水平分别为 (5.98±1.04) 、 (9.41±1.58) mmol/L, 对照组FPG、PPG水平分别为 (6.23±0.92) 、 (9.57±1.67) mmol/L;两组FPG、PPG水平均低于本组治疗前, 差异具有统计学意义 (P＜0.05) ;两组FPG、PPG水平对比, 差异无统计学意义 (P＞0.05) .观察组血糖达标时间 (2.81±0.26) d短于对照组的 (3.24±0.64) d, 胰岛素日用量 (0.65±0.07) IU/kg少于对照组的 (0.79±0.06) IU/kg, 低血糖事件发生率13.33％低于对照组的43.33％, 差异均具有统计学意义 (P＜0.05) .结论 甘精胰岛素与中效人胰岛素均可有效地控制老年2型糖尿病患者的血糖, 因前者低血糖发生率低、胰岛素用量较少、血糖达标时间短, 老年2型糖尿病患者更受益.
展开▼
